The Online International Journal of Onco Scientific Networks & Oncology is a peer-reviewed open acess journal that publishes original research articles as well as review articles in all areas of Oncology. this practical journal also includes information on new products, new therapies and patient management, as well as reviews of the latest research. Cancer is a complex problem. The international effort to understand and control it involves clinicians trained in many branches of medicine and scientists from most biological disciplines, chemistry, pharmaceutical and physical sciences The International Online Journal of Cancer & Therapeutics exists to serve the needs of this diverse community, providing a forum for prompt communication of original and innovative research findings that have relevance to understanding the etiology of cancer and to improving the treatment and survival of patients.
The journal publishes important original studies, reviews, and perspectives within the major topic areas of biology of premalignancy, risk factors and risk assessment, early detection research, immunoprevention, and chemopreventive and other interventions, including the basic science behind them. This journal comprises preclinical, clinical and translational research, with special attention given to molecular discoveries and an emphasis on building a translational bridge between the basic and clinical sciences. Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting.
Oncology is the diagnosis and treatment of cancers,including breast,prostate,colon,lung and ovarian cancers as well as brain tumors,leukemia,lymphoma and many other types of cancer.. A doctor who works in the field of oncology is called an oncologist. The primary regions of oncology are radiation, which is worried with radiation treatment, or radiotherapy; surgical, which is contained specialists who spend significant time in tumor evacuation; therapeutic, which manages disease drugs, including chemotherapy; and interventional, which includes interventional radiologists who have some expertise in insignificantly obtrusive picture guided tumor treatment.
It is our pleasure to welcome you on behalf of the editorial board members,Professors,Scientists... it is with great pleasure, humility and honour that we welcome you to this inaugural first issue of Journal of Cancer & Therapeutics. Hosted by the Helics Scientific Networks and Cancer Leadership 2018.
The journal has a strong emphasis on interdisciplinary issues reflecting the complexity of Cancer & Therapeutics. Today, Cancer & Therapeutics are a very broad research area involving different scientific disciplines ranging , to basic sciences and from medicine to marketing. In each of this areas there are different journals dealing with very specific aspects intended for a limited audience. Similarly, interdisciplinary researches are often difficult to publish in specialized journals and part of the aim of Journal of Cancer & Therapeutics is to capture high-quality works that doesn’t clearly fall within the scope of other journals. This openminded stance toward the scope of the journal allows to overcome knowledge fragmentation and the integration between apparently different topics providing the reader with a global view on the topic of interest.
We delighted to be a part of this new interdisciplinary initiative, which we believe is exactly the type of platform needed to highlight and broaden Cancer & Therapeutics into widespread acceptance with the highest values of scientific integrity to which the Journal of Cancer & Therapeutics is inspired.
Once more, on behalf I welcome you to this journal. We look forward to your submissions and to publish your manuscripts.
The Online International Journal of Onco Scientific Networks & Oncology aims to publish scientific articles in General Medicine. It covers the entire spectrum from basic science to clinical medicine, including research papers, case reports and review articles as special articles.
For scientific research work constantly, but also an integrative review of all the work and results obtained in relation to a particular topic that will generate a real knowledge about that is not only necessary.
Track: 1 Cell and Tumor Biology
Track: 2 Carcinogenesis
Track: 3 Cancer Genomics, Epigenetic and Genomic Instability
Track: 4 Prevention and Early Detection
Track: 5 Radio-biology / Radiation Oncology
Track: 6 Molecular Pathology Approach to Cancer
Track: 7 Molecular and Genetic Epidemiology
Track: 8 Experimental / Molecular Therapeutics, Pharmacogenomics
Track: 9 Cancer Research & Cancer Metabolism
Track: 10 Intraoperative Imaging Technologies for Cancer Detection and Treatment
Track: 11 Methods in Clinical Cancer Research
Track: 12 Tumour Immunology
Track: 13 Paradigms in Interventional Pulmonology Ultrasound & Lung Cancer Staging
Track: 14 Uro Oncology
Track: 15 Cancer Nursing
Track: 16 Gastrointestinal (GI) Cancer
Track: 17 Gynaecological Oncology
Track: 18 Breast Cancer
Track: 19 Cancer Vaccines and Immunoengineering
Track: 20 Lung Cancer
Cancer Scientific Networks:
Cancer Leadership & Committees consider proposals for Special Issues Editors will return a decision on your proposal within Two weeks of receipt. To enrich our vision of making the scientific information available at an ease of access, Cancer Leadership & Committees initiated special issue for the open access journals. All the articles published under a special issue focuses on a single topic providing the complete information about the ongoing research providing more insight on an emphasized topic of research enabling the readers access wide forecasted information on a particular topic Issue.
Special Issue Proposals: Special Issue deals with focused research topics of high interest, falling under the scope of the Journal. Special Issues are the pool of articles under a current topic selected from the Ongoing Research under specific discipline. The aim of the Special Issue is to provide a platform for the researchers to understand the recent advancements and challenges in particular areas of research. These articles will provide an opportunity to the readers to understand and access the scientific information.
We encourage potential scientists to organize the Special Issue in their field of interests that fits within the Journal scope. This will provide an opportunity to increase the visibility of the Guest Editors. The Special Issue Titles may be from any basic and clinical area of Science, Technology and Medicine. People interested in publishing a special issue are advised to consider the following guidelines.
Your proposal should contain:
By submitting a Special Issue proposal to Cancer Leadership & Committees, you agree to abide by the Special Issue Editor Protocol should your proposal be accepted
Special issue articles are published immediately upon their acceptance and are released under upcoming regular issues. Special Issues are invited throughout the year. For more information or any queries about the special issues, please write us to firstname.lastname@example.org or email@example.com
Promoting Your Special Issue
Cancer Leadership & Committees will work with Guest Editors to increase the visibility of the Special Issue in the months leading up to the submission deadline and once it has been published.
What Cancer Leadership & Committees will do:
1. Cancer Leadership & Committees will circulate your Call for Papers to the Cancer Editorial Board, targeted mailing lists, and relevant AoM listservs. It will also advertise your Call on the Cancer websites and other social media platforms. It will re-issue the Call at appropriate intervals.
2. Once the Special Issue is published, announcements will be made to the Cancer Editorial Board, targeted mailing lists, and relevant AoM listservs as well as on the Cancer websites social media platforms.
3. Free access to the Special Issue will be made available in the website to Guest Editors and readers.
What is expected of Guest Editors?
1. We expect that Guest Editors will circulate the Call for Papers within their own personal networks, social media groups, and at any relevant conferences or workshops they may attend.
2. If it has not already been suggested as part of the proposal, consideration should be given to organizing a conference or workshop either to generate submissions or to aid in the development of submitted papers. A symposium or PDW at a well-known conference may also be considered.
3. We expect Guest Editors to identify up to 50 scholars for whom the Special Issue will be particularly relevant
If you have any queries, please contact Eliza Lind (Cancer.firstname.lastname@example.org)
Dec 2003 - Awarded Dottorato (PhD) in ‘Molecular Pathology and Tumor Morphology’,
University “G. d’Annunzio” of Chieti and Pescara, Chieti, Italy.
May 1999 - Gained Teachers’ Certificate (Biology), University of L’Aquila, L’Aquila, Italy.
Oct 1997 - Awarded Biological Science Degree (107/110), University of L’Aquila, L’Aquila, Italy.
P27 Monterisi S, Lobo MJ, Livie C, Brescia M, Castle JC, Weinberger M, Baillie G, Musheshe N, Stangherlin A, Maizel R, Bortolozzi M, Micaroni M, Zaccolo M. Phosphodiesterase 2A2 regulates mithocondria morphology and apoptotic cell death via local modulation of cAMP/PKA signaling. eLife 2017; 6: e21374. SJR: 5.984 IF: 7.725
P26 Lampis S, Zonaro E, Bertolini C, Cecconi D, Monti F, Micaroni M, Turner RJ, Butler CS, Vallini G. Selenite biotransformation and detoxification by Stenotrophomonas maltophilia SelTE02: novel clues on the route to bacterial biogenesis of selenium nanoparticles. J. Hazard Mat. 2017; 324 (part A): 3-14. SJR: 1.727 IF: 6.065
P25 Micaroni M, Giacchetti G, Plebani R, Xiao GG, Federici L. ATP2C1 gene mutations in Hailey-Hailey disease and possible roles of SPCA1 isoforms in membrane trafficking.
Cell Death Dis. 2016; 7 (6): e2259. Review SJR: 2.536 IF: 5.965
P24 Micaroni M. Misinterpretation of ATP2C1 gene mutations.
Indian J. Dermatol. Venereol. Leprol. 2016; 82 (3): 306-307. SJR: 0.590 IF: 1.948
P23 Micaroni M. Correct reading frame helps to properly identify ATP2C1 gene mutations vs. polymorphisms. Clin. Exper. Dermatol. 2016; 41 (5): 558-559. SJR: 0.522 IF: 1.589
P22 Yu CH, Micaroni M, Puyskens A, Schultz TE, Yeo JC, Stanley AC, Lucas M, Kurihara J, Dobos KM, Stow JL, Blumenthal A. RP105 engages phosphatidylinositol 3-kinase p110δ to facilitate the trafficking and secretion of cytokines in macrophages during mycobacterial infection. J. Immunol. 2015; 195 (8): 3890-3900. SJR: 3.568 IF: 4.985
P21 Soro V, Dutton LC, Sprague SV, Nobbs AH, Ireland AJ, Sandy JR, Jepson MA, Micaroni M, Splatt PR, Dymock D, Jenkinson HF. Axenic culture of a candidate division TM7 bacterium from the human oral cavity and biofilm interactions with other oral bacteria. Appl. Environ. Microbiol. 2014; 80 (20): 6480-6489. SJR: 1.862 IF: 3.668
P20 Stanley AC, Wong CX, Micaroni M, Venturato J, Khromykh T, Stow JL, Lacy P. The Rho GTPase Rac1 is required for recycling endosome-mediated secretion of TNF in macrophages. Immunol. Cell Biol. 2014; 92 (3): 275-286. SJR: 2.402 IF: 4.147
P19 Micaroni M, Stanley AC, Khromykh T, Venturato J, Wong CX, Lim JP, Marsh BJ, Storrie B, Gleeson PA, Stow JL. Rab6a/a' are important Golgi regulators of pro-inflammatory TNF secretion in macrophages. PLoS One 2013; 8 (2): e57034. SJR: 1.740 IF: 3.534
P18 Fusella A*, Micaroni M*, Di Giandomenico D, Mironov AA, Beznoussenko GV. Segregation of Qb-SNAREs GS27 and GS28 in Golgi vesicles regulates intra-Golgi transport. Traffic 2013; 14 (5): 568-584. SJR: 3.757 IF: 4.714
P17 Micaroni M, Malquori L. Overlapping ATP2C1 and ASTE1 genes in human genome: implications for SPCA1 isoforms expression? Int. J. Mol. Sci. 2013; 14 (1): 674-683. SJR: 0.762 IF: 2.339
P16 Di Paola S, Micaroni M, Di Tullio G, Buccione R, Di Girolamo M. PARP16/ARTD15 is a novel endoplasmic-reticulum-associated mono-ADP-ribosyltransferase that interacts with, and modifies karyopherin-β1.
PLoS One 2012; 7 (6): e37352. SJR: 1.945 IF: 3.730
P15 Micaroni M. Calcium around the Golgi apparatus: implications for intracellular membrane trafficking. Adv. Exp. Med. Biol. 2012; 740 (18): 439-460. Review SJR: 0.747 IF: 1.825
P14 Storrie B, Micaroni M, Morgan GP, Jones N, Kamykowski JA, Wilkins N, Pan TH, Marsh BJ. Electron tomography reveals Rab6 is essential to the trafficking of trans-Golgi clathrin and COPI- coated vesicles and the maintenance of Golgi cisternal number.
Traffic 2012; 13 (5): 727-744. SJR: 3.903 IF: 4.652
P13 Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L, Micaroni M, Chaneton B, Adam J, Hedley A, Kalna G, Tomlinson IPM, Pollard PJ, Watson DG,
Deberardinis RJ, Shlomi T, Ruppin E, Gottlieb E. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 2011; 477 (7363): 225-228. SJR: 17.348 IF: 36.280
P12 Micaroni M. The role of calcium in intracellular trafficking. Curr. Mol. Med. 2010; 10 (8): 763- 773. Review SJR: 2.514 IF: 5.212
P11# Micaroni M, Mironov AA. Roles of Ca2+ and secretory pathway Ca2+-ATPase pump type 1 (SPCA1) in intra-Golgi trafficking. Commun. Integr. Biol. 2010; 3 (6): 504-507. mini-Review SJR: 0.731
P10 Micaroni M, Perinetti G, Berrie CP, Mironov AA. The SPCA1 Ca2+-pump and intracellular membrane trafficking. Traffic 2010; 11 (10): 1315-1333. SJR: 4.461 IF: 5.278
P9 Micaroni M, Perinetti G, Di Giandomenico D, Bianchi K, Spaar A, Mironov AA. Synchronous intra-Golgi transport induces release of Ca2+-from the Golgi apparatus.
Exp. Cell Res. 2010; 316 (13): 2071-2086. SJR: 2.385 IF: 3.609
P8 Weller SG, Capitani M, Cao H, Micaroni M, Luini A, Sallese M, McNiven MA. Src kinase regulates the integrity and function of the Golgi apparatus via activation of dynamin 2. Proc. Natl. Acad. Sci. USA 2010; 107 (13): 5863-5868. SJR: 6.769 IF: 9.771
P7 Boncompagni S, Rossi AE, Micaroni M, Hamilton SL, Dirksen RT, Franzini-Armstrong C, Protasi F. Characterization and temporal development of cores in a mouse model of a malignant hyperthermia. Proc. Natl. Acad. Sci. USA 2009; 106 (51): 21996-22001. SJR: 6.913 IF 9.432
P6 # Orso G, Pendin D, Liu S, Tosetto J, Moss TJ, Faust JE, Micaroni M, Egorova A, Martinuzzi A, McNew JA, Daga A. Homotypic fusion of ER membranes requires the dynamin-like GTPase atlastin. Nature 2009; 460 (7258): 978-983. FFa:12 SJR: 14.804 IF: 34.480
P5 Boncompagni S, Rossi AE, Micaroni M, Beznoussenko GV, Polishchuk RS, Dirksen RT, Protasi F. Mitochondria are linked to calcium stores in striated muscle by developmentally regulated tethering structures. Mol. Biol. Cell 2009; 20 (3): 1058-1067. SJR: 5.779 IF: 5.979
P4 Beznoussenko GV, Dolgikh VV, Seliverstova EV, Semenov PB, Tokarev YS, Trucco A, Micaroni M, Di Giandomenico D, Auinger P, Senderskiy IV, Skarlato SO, Snigirevskaya ES, Kommissarchik YY, Pavelka M, De Matteis MA, Luini A, Sokolova YY, Mironov AA. Analogs of the Golgi complex in microsporidia: structure and avesicular mechanisms of function. J. Cell Science 2007; 120 (7): 1288-1298. SJR: 5.386 IF: 6.383
P3 # Frezza C, Cipolat S, Martins de Brito O, Micaroni M, Beznoussenko GV, Rudka T, Bartoli D, Polishchuk RS, Danial NN, De Strooper B, Scorrano L. OPA1 controls apoptotic cristae remodelling independently from mitochondrial fusion.
Cell 2006; 126 (1): 177-189. FFa: 9 SJR: 23.449 IF: 29.194
P2 # Kweon HS, Beznoussenko GV, Micaroni M, Polishchuk RS, Trucco A, Martella O, Di Giandomenico D, Marra P, Fusella A, Di Pentima A, Berger EG, Geerts WJC, Koster AJ, Burger KNJ, Luini A, Mironov AA. Golgi enzymes are enriched in perforated zones of Golgi cisternae but excluded from COP-I vesicles. Mol. Biol. Cell 2004; 15 (10): 4710-4724. FFa: 8 SJR: 6.469 IF: 7.517
P1 De Giovanni C, Landuzzi L, Nicoletti G, Astolfi A, Croci S, Micaroni M, Nanni P, Lollini PL. APC10.1: an APCMIN/+ intestinal cell line with retention of heterozygosity.
Int. J. Cancer 2004; 109 (2): 200-206. SJR: 1.978 IF: 4.416